How to buy Syros Pharmaceuticals stock (SYRS)

Syros Pharmaceuticals is a biotechnology business based in the US. Syros Pharmaceuticals shares (SYRS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.20 – a decrease of 3.47% over the previous week. Syros Pharmaceuticals employs 68 staff and has a trailing 12-month revenue of around $386,000.

Our top picks for where to buy Syros Pharmaceuticals stock

Buy Syros Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Syros Pharmaceuticals stock price (NASDAQ: SYRS)

Use our graph to track the performance of SYRS stocks over time.

Syros Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$0.20
52-week range	$0.18 - $8.17
50-day moving average more info button	$1.30
200-day moving average more info button	$3.75
Wall St. target price	$1.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-3.07

Is it a good time to buy Syros Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Syros Pharmaceuticals price performance over time

Historical closes compared with the close of $0.2018 from 2024-12-19

1 week (2024-12-13)	-2.61%
1 month (2024-11-22)	-31.17%
3 months (2024-09-20)	-89.65%
6 months (2024-06-21)	-96.38%

1 year (2023-12-21)	-96.51%
2 years (2022-12-21)	-93.49%
3 years (2021-12-21)	35.6
5 years (2019-12-20)	70.3

Syros Pharmaceuticals financials

Revenue TTM	$386,000
Gross profit TTM	$14.9 million
Return on assets TTM	-59.88%
Return on equity TTM	-776.96%
Profit margin	0%
Book value	$-0.42
Market Capitalization more info button	$5.6 million

TTM: trailing 12 months

Syros Pharmaceuticals share dividends

We're not expecting Syros Pharmaceuticals to pay a dividend over the next 12 months.

Have Syros Pharmaceuticals's shares ever split?

Syros Pharmaceuticals's shares were split on a 1:10 basis on 18 September 2022 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Syros Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Syros Pharmaceuticals shares which in turn could have impacted Syros Pharmaceuticals's share price.

Syros Pharmaceuticals share price volatility

Over the last 12 months, Syros Pharmaceuticals's shares have ranged in value from as little as $0.183 up to $8.17. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Syros Pharmaceuticals's is 1.592. This would suggest that Syros Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Syros Pharmaceuticals overview

Syros Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Syros Pharmaceuticals is owned by insiders or institutions?
Currently 0.739% of Syros Pharmaceuticals shares are held by insiders and 75.589% by institutions. How many people work for Syros Pharmaceuticals?
Latest data suggests 68 work at Syros Pharmaceuticals. When does the fiscal year end for Syros Pharmaceuticals?
Syros Pharmaceuticals's fiscal year ends in December. Where is Syros Pharmaceuticals based?
Syros Pharmaceuticals's address is: 35 CambridgePark Drive, Cambridge, MA, United States, 02140 What is Syros Pharmaceuticals's ISIN number?
Syros Pharmaceuticals's international securities identification number is: US87184Q1076 What is Syros Pharmaceuticals's CUSIP number?
Syros Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 87184Q107